US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 17:49:26 Source:healthViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- Yu Darvish extends scoreless innings streak to 25 in Padres' 9
- Flood relief work strengthened in China's Guangdong
- Xi calls on Chongqing to write its chapter in Chinese modernization
- Obstacles remain as women seek more leadership roles in America's Black Church
- Adams, Reyna, Turner, Ream are US concerns ahead of Copa America
- Exploring ancient charms of Guizhou: A journey to Hongyang village
- Liang seals narrow win as WTT Champions Incheon kick off
- China announces visa
- Supreme Court rejects an appeal from a Canadian man once held at Guantanamo